About MBX Biosciences, Inc. Common Stock
https://mbxbio.comMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
CEO
Peter Kent Hawryluk MBA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 74
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:6.65M
Value:$285.97M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.82M
Value:$207.36M
ORBIMED ADVISORS LLC
Shares:4M
Value:$172.08M
Summary
Showing Top 3 of 118
About MBX Biosciences, Inc. Common Stock
https://mbxbio.comMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $23.93M ▲ | $-21.62M ▼ | 0% | $-0.63 ▼ | $-21.57M ▲ |
| Q2-2025 | $0 | $21.8M ▼ | $-19.41M ▲ | 0% | $-0.58 ▲ | $-21.74M ▲ |
| Q1-2025 | $0 | $26.53M ▲ | $-23.88M ▼ | 0% | $-0.71 ▼ | $-26.45M ▼ |
| Q4-2024 | $0 | $18.61M ▼ | $-15.59M ▲ | 0% | $-0.47 ▲ | $-18.55M ▲ |
| Q3-2024 | $0 | $19.61M | $-18.14M | 0% | $-0.54 | $-19.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $391.67M ▲ | $400.08M ▲ | $12.54M ▲ | $387.54M ▲ |
| Q2-2025 | $224.91M ▼ | $231.52M ▼ | $12.28M ▲ | $219.24M ▼ |
| Q1-2025 | $240.79M ▼ | $245.93M ▼ | $10.5M ▼ | $235.42M ▼ |
| Q4-2024 | $262.15M ▼ | $268.54M ▼ | $11.09M ▲ | $257.44M ▼ |
| Q3-2024 | $277.06M | $282.4M | $11.03M | $271.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.62M ▼ | $-21.54M ▼ | $17.06M ▼ | $187.82M ▲ | $183.34M ▲ | $-21.93M ▼ |
| Q2-2025 | $-19.41M ▲ | $-17.43M ▲ | $25.99M ▲ | $1.33M ▲ | $9.88M ▲ | $-18.14M ▲ |
| Q1-2025 | $-23.88M ▼ | $-22.68M ▼ | $3.23M ▲ | $4K ▲ | $-19.45M ▲ | $-22.71M ▼ |
| Q4-2024 | $-15.59M ▲ | $-16.04M ▼ | $-67.34M ▲ | $-132K ▼ | $-83.51M ▼ | $-16.13M ▼ |
| Q3-2024 | $-18.14M | $-14.66M | $-100.79M | $235.81M | $120.36M | $-14.72M |
CEO
Peter Kent Hawryluk MBA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 74
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:6.65M
Value:$285.97M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.82M
Value:$207.36M
ORBIMED ADVISORS LLC
Shares:4M
Value:$172.08M
Summary
Showing Top 3 of 118